Vanguard Group Inc. Has $546.05 Million Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Vanguard Group Inc. trimmed its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 8.8% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 18,478,744 shares of the company’s stock after selling 1,778,372 shares during the quarter. Vanguard Group Inc. owned about 8.32% of Hims & Hers Health worth $546,047,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. UMB Bank n.a. grew its stake in Hims & Hers Health by 247.5% during the first quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock worth $39,000 after purchasing an additional 933 shares during the period. Larson Financial Group LLC lifted its holdings in Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after acquiring an additional 458 shares during the period. Tsfg LLC bought a new stake in Hims & Hers Health during the first quarter worth $46,000. Fifth Third Bancorp lifted its holdings in Hims & Hers Health by 165.4% during the first quarter. Fifth Third Bancorp now owns 1,542 shares of the company’s stock worth $46,000 after acquiring an additional 961 shares during the period. Finally, N.E.W. Advisory Services LLC bought a new stake in Hims & Hers Health during the first quarter worth $49,000. 63.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HIMS. Piper Sandler reiterated a “neutral” rating and set a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Citigroup reiterated a “sell” rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Bank of America boosted their target price on Hims & Hers Health from $22.00 to $26.00 and gave the company an “underperform” rating in a research note on Tuesday, April 29th. Wall Street Zen lowered Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $40.00 target price on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health presently has an average rating of “Hold” and an average target price of $39.83.

Insider Transactions at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 23,107 shares of the stock in a transaction dated Monday, June 23rd. The stock was sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the completion of the sale, the chief financial officer directly owned 63,222 shares in the company, valued at $2,987,239.50. This represents a 26.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Chi sold 17,102 shares of the stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total value of $1,021,844.50. Following the sale, the insider owned 278,654 shares of the company’s stock, valued at $16,649,576.50. This represents a 5.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,273,034 shares of company stock valued at $66,425,573 over the last quarter. 13.71% of the stock is owned by company insiders.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $47.14 on Friday. Hims & Hers Health, Inc. has a 52 week low of $13.47 and a 52 week high of $72.98. The business has a 50-day simple moving average of $53.16 and a 200 day simple moving average of $45.44. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The stock has a market cap of $10.55 billion, a price-to-earnings ratio of 58.92, a PEG ratio of 3.06 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%. The firm had revenue of $544.83 million during the quarter, compared to analysts’ expectations of $550.06 million. During the same quarter in the previous year, the company posted $0.06 earnings per share. Hims & Hers Health’s revenue for the quarter was up 72.6% compared to the same quarter last year. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.